127 related articles for article (PubMed ID: 8984604)
1. [Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients].
Meyer BJ
Schweiz Med Wochenschr; 1996 Nov; 126(46):1961-9. PubMed ID: 8984604
[TBL] [Abstract][Full Text] [Related]
2. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
Van de Werf F
Thromb Haemost; 1997 Jul; 78(1):210-3. PubMed ID: 9198155
[TBL] [Abstract][Full Text] [Related]
4. Drugs for percutaneous coronary interventions.
Med Lett Drugs Ther; 2004 Dec 6-20; 47(1197-1198):100-2. PubMed ID: 15583527
[TBL] [Abstract][Full Text] [Related]
5. [New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)].
Schächinger V; Zeiher AM
Z Kardiol; 1995 Sep; 84(9):651-67. PubMed ID: 8525667
[TBL] [Abstract][Full Text] [Related]
6. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
7. Optimal antithrombotic treatment for percutaneous coronary intervention.
Kadakia RA; Ferguson JJ
Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
[TBL] [Abstract][Full Text] [Related]
8. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
[TBL] [Abstract][Full Text] [Related]
9. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
10. [Clinical use of glycoprotein IIb/IIIa receptor blockers in invasive cardiology].
Cervinka P
Vnitr Lek; 1998 Jul; 44(7):439-43. PubMed ID: 9748884
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Ferguson JJ; Wilson JM; Diez J
Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
[TBL] [Abstract][Full Text] [Related]
12. [Clinical studies on glycoprotein IIb/IIIa receptor antagonist].
Rasmussen LH; Husted SE; Clemmensen PM; Gøtzsche CO; Helqvist S; Kristensen SD; Pedersen KE; Rasmussen K; Rasmussen S
Ugeskr Laeger; 2000 Oct; 162(44):5944-7. PubMed ID: 11094564
[TBL] [Abstract][Full Text] [Related]
13. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
[TBL] [Abstract][Full Text] [Related]
14. The role of platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures.
Dangas G; Fuster V
Rev Port Cardiol; 1999 Feb; 18 Suppl 1():I49-53. PubMed ID: 10191675
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet and anticoagulant therapy in patients undergoing percutaneous transluminal coronary angioplasty.
Barry WL; Sarembock IJ
Cardiol Clin; 1994 Aug; 12(3):517-35. PubMed ID: 7805084
[TBL] [Abstract][Full Text] [Related]
16. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
Byrne A; Moran N; Maher M; Walsh N; Crean P; Fitzgerald DJ
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3224-9. PubMed ID: 9409315
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Bassand JP
Haemostasis; 2000; 30 Suppl 2():114-21; discussion 106-7. PubMed ID: 11251354
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic treatment in acute coronary syndromes.
Hoole SP; Saw J
Minerva Med; 2010 Aug; 101(4):215-38. PubMed ID: 21030935
[TBL] [Abstract][Full Text] [Related]
19. [Advances in adjunctive pharmacological therapy for percutaneous coronary interventions].
Benito B; Masotti M; Betriu A
Rev Esp Cardiol; 2005 Jun; 58(6):729-43. PubMed ID: 15970124
[TBL] [Abstract][Full Text] [Related]
20. New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials.
Cohen M
Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S343-52. PubMed ID: 9628448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
